Gu17Lys levels were High, 41%; Medium, 14%; Low, 3% and Zero, 0% for this experiment. C) Results from a second experiment with the same PS75 fibroblast cultures treated and analyzed as described in a. Mutation levels were High, 32%; Medium, 4%; Low, 2% and Zero, 0% for this experiment. Supplementary Fig. 4 . Additional experiments (a and b) showed pAKT and pPRAS40 levels were reduced within 2 hours of treatment with 125 nM ARQ 092. Both experiments were performed as described for Fig. 3 . Insets in the pAKT histograms show the ratios from the ARQ 092-treated cells using a smaller scale. For both experiments, pAKT levels from CL1 grown without serum begin to rise at 8 hours compared to levels at the 2 or 4 hour time points. CL1, clone 1 (mutation-positive, blue bars); CL2, clone 2 (mutation-negative, red bars), ser, grown with serum (solid bars); NS, grown without serum (shaded bars). Supplementary Fig. 6 . Serum stimulation in cells treated with ARQ 092 resulted in elevated levels of pAKT and pPRAS40. Mutation-positive (clone 1) and negative (clone 2) SCC were serum starved, treated +/-ARQ 092 and stimulated with 10% serum as described in the Methods. Cells were collected at 10 minutes, 2 hours and 24 hours after PDGF-BB addition. a) Infrared images of western hybridizations using the indicated antibodies. 10, 10 minutes, 2, 2 hours, 24, 24 hours. b) Histograms of the ratios of the infrared signals for each antibody pair. Signals for both clones +/-ARQ 092 treatment are graphed together on the left. Signals for ARQ 092-treated clones are also graphed on the right using a smaller scale. Serum addition increased pAKT levels 5-to >70-fold in ARQ 092-treated and 7-to >100-fold in untreated clone 2 cells compared to un-stimulated cells. Serum addition increased pAKT levels <2-to 10-fold in ARQ 092-treated and less than two-to fourfold in untreated clone 1 cells compared to un-stimulated cells. For pPRAS40, serum addition increased ARQ 092-treated clone 1 levels three-to eightfold and untreated clone 1 levels less than twofold. Serum addition increased pPRAS40 levels 11-to 15-fold in ARQ 092-treated and 8-to 25-fold in untreated clone 2 compared to un-stimulated cells. Supplementary Fig 7. Counting of cells showed that high concentrations of ARQ 092 were needed to reduce viability of cells from patients with Proteus syndrome. Mutation-positive and negative SCC were grown in high (10%) or low (0.5%) serum with increasing concentrations of ARQ 092 followed by manual cell counting as described in the Methods. CL1, clone 1 (mutation-positive); CL2, clone 2 (mutation-negative); HS, high serum; LS, low serum 
